Risk of multiple sclerosis in patients with psoriasis: A Danish nationwide cohort study

Journal of Investigative Dermatology

Volumn 136, Issue 1, 2016, Pages 93-98

  Egeberg, Alexander ^a   Mallbris, Lotus ^b   Gislason, Gunnar Hilmar ^a,c,d   Skov, Lone ^a   Hansen, Peter Riis ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c The Danish Heart Foundation   (Denmark)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; USTEKINUMAB;

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE SEVERITY; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; INFLAMMATORY BOWEL DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; SENSITIVITY ANALYSIS; SMOKING; SOCIAL STATUS; AGE DISTRIBUTION; AGED; CHI SQUARE DISTRIBUTION; COMORBIDITY; CONFIDENCE INTERVAL; DENMARK; INCIDENCE; MIDDLE AGED; POISSON DISTRIBUTION; PROGNOSIS; REGISTER; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX RATIO; YOUNG ADULT;

ADULT; AGE DISTRIBUTION; AGED; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; COMORBIDITY; CONFIDENCE INTERVALS; DENMARK; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POISSON DISTRIBUTION; PROGNOSIS; PSORIASIS; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; YOUNG ADULT;

EID: 84959459779     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/JID.2015.350     Document Type: Article

References (33)

1. Ahlehoff O, Gislason GH, Jorgensen CH, et al. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. Eur Heart J 2012;33:2054-64.
2. Ali R, Nicholas RS, Muraro PA. Drugs in development for relapsing multiple sclerosis. Drugs 2013;73:625-50.
3. Andersen TF, Madsen M, Jorgensen J, et al. The Danish National Hospital Register. A valuable source of data for modern health sciences. Danish Med Bull 1999;46:263-8.
4. Armstrong AW, Harskamp CT, Dhillon JS, et al. Psoriasis and smoking: a systematic review and meta-analysis. Br J Dermatol 2014;170:304-14.
5. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol 2007;61:504-13.
6. Barcellos LF, Kamdar BB, Ramsay PP, et al. Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study. Lancet Neurol 2006;5:924-31.
7. Brucklacher-Waldert V, Stuerner K, Kolster M, et al. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 2009;132:3329-41.
8. Calabresi PA, Wilterdink JL, Rogg JM, et al. An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology 2002;58:314-7.
9. Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007;80:273-90.
10. Dobson R, Giovannoni G. Autoimmune disease in people with multiple sclerosis and their relatives: a systematic review and meta-analysis. J Neurol 2013;260:1272-85.
11. Fellner A, Dano M, Regev K, et al. Multiple sclerosis is associated with psoriasis. A case-control study. J Neurol Sci 2014;338:226-8.
12. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Danish Med Bull 1997;44:445-8.
13. Ghoreschi K, Bruck J, Kellerer C, et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 2011;208:2291-303.
14. Gooderham M, Posso-De Los Rios CJ, Rubio-Gomez GA, et al. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review. Skin Ther Lett 2015;20:1-5.
15. Hofman FM, Hinton DR, Johnson K, et al. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 1989;170:607-12.
16. Hvidtfeldt UA, Gerster M, Knudsen LB, et al. Are low Danish fertility rates explained by changes in timing of births? Scand J Public Health 2010;38:426-33.
17. Kimball AB, Leonardi C, Stahle M, et al. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). Br J Dermatol 2014;171:137-47.
18. Kwok T, Jing Loo W, Guenther L. Psoriasis and multiple sclerosis: is there a link? J Cutan Med Surg 2010;14:151-5.
19. Lopez-Lerma I, Iranzo P, Herrero C. New-onset psoriasis in a patient treated with interferon beta-1a. Br J Dermatol 2009;160:716-7.
20. Lozeron P, Denier C, Lacroix C, et al. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 2009;66:490-7.
21. Marrie RA, Reider N, Cohen J, et al. A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. Mult Scleros 2015;21:282-93.
22. Mason K, Thygesen LC, Stenager E, et al. Evaluating the use and limitations of the Danish National Patient Register in register-based research using an example of multiple sclerosis. Acta Neurol Scand 2012;125:213-7.
23. Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 2012;11:763-76.
24. Ni C, Chiu MW. Psoriasis and comorbidities: links and risks. Clin Cosmet Invest Dermatol 2014;7:119-32.
25. Nickoloff BJ, Karabin GD, Barker JN, et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol 1991;138:129-40.
26. Nunez C, Dema B, Cenit MC, et al. IL23R: a susceptibility locus for celiac disease and multiple sclerosis? Genes Immun 2008;9:289-93.
27. Pihl-Jensen G, Tsakiri A, Frederiksen JL. Statin treatment in multiple sclerosis: a systematic review and meta-analysis. CNS Drugs 2015;29:277-91.
28. Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 2014;29:541-9.
29. Selmaj KW, Raine CS. Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors. Neurology 1995;45:S44-9.
30. Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 1991;325:467-72.
31. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999;53:457-65.
32. Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008;172:146-55.
33. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453-7.